Tag Archives: forecast
By Pharm Exec | Published: July 29, 2014
The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.
By William Looney | Published: July 23, 2014
After fading to dreary summer stock for the past few years, dealmaking is today back to center stage, but with the major roles reversed— small biotech, yesterday’s understudy, now gets top billing, while big Pharma has to work harder for its close-up. Pharm Exec brought partner Campbell Alliance and a select group of West Coast […]
By Guest Blogger | Published: July 15, 2014
By Colin McMahon. EvalutePharma’s seventh edition of its World Preview documents that worldwide prescription drug sales forecast will exceed the one trillion dollar mark by 2020. The company bases this estimate on the growing compound annual growth rate (CAGR) that the pharmaceutical industry is currently enjoying. It predicts that CAGR will continue to grow through […]
By Pharm Exec | Published: June 18, 2014
Big Pharma employment dropped by 3 percent in the decade 2003–2013, allaying fears that industry consolidation and restructuring would lead to significantly reduced headcounts and payrolls, a report by EP Vantage reveals. The report shows that when it comes to pharmaceutical industry jobs, Big Biotech and specialty drugmakers are growing in significance, more than offsetting the […]
By Pharm Exec | Published: June 17, 2014
A new report from GlobalData states that the increase of biosimilars will have a negative impact on the biologics market after 2019. The report cites patent expirations of branded biologics and regulatory clarification as reasons for the prediction that biosimilars will capture the market share after 2019.